Karyopharm Therapeutics | KPTI - Sales Revenues


Karyopharm Therapeutics reported $34.08M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
AbbVie USD 16.62B 840M Dec/2025
Abbott USD 11.46B 90M Dec/2025
Amgen USD 9.9B 340M Dec/2025
AstraZeneca USD 15.5B 313M Dec/2025
BioCryst Pharmaceuticals USD 406.56M 247.16M Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Enanta Pharmaceuticals USD 16.96M 50.68M Dec/2024
GlaxoSmithKline GBP 8.62B 73M Dec/2025
Incyte USD 1.51B 140M Dec/2025
J&J USD 24.1B 500M Mar/2026
Karyopharm Therapeutics USD 34.08M 3.54M Dec/2025
MacroGenics USD 41.23M 31.61M Dec/2025
Merck USD 16.4B 880M Dec/2025
Nektar Therapeutics USD 21.81M 2.32M Dec/2025
Novartis USD 13.86B 50M Dec/2025
Novartis USD 13.86B 498M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
Sangamo BioSciences USD 356K 125K Jun/2024
Takeda JPY 1.19T 80B Dec/2025
Tectonic Therapeutic USD 0 0 Dec/2024
TG Therapeutics USD 192.57M 30.87M Dec/2025
Ultragenyx Pharmaceutical USD 207M 47M Dec/2025
Xencor USD 28.24M 7.24M Dec/2025